Tukysa (tucatinib) — Medica
Biliary tract cancer
Initial criteria
- Patient is age ≥ 18 years
- Patient has unresectable or metastatic disease
- Patient has human epidermal growth factor receptor 2 (HER2)-positive disease
- Patient has tried at least one systemic regimen
- Medication is used in combination with trastuzumab
Approval duration
1 year